When an adult enters residential treatment for alcohol use disorder, medication is often part of the clinical plan within the first week. Naltrexone in residential alcohol treatment for adults is one of three medications the FDA has approved for alcohol use disorder, and it is the one most commonly started while a person is still in a structured, 24/7 monitored setting. Our clinical and admissions teams field the same questions almost daily: how does naltrexone actually work, when is it safe to start after withdrawal, and does it replace therapy? It does not replace therapy. Used well, it lowers the biological pull toward drinking so that psychological, psychiatric, and trauma work has room to take hold.

What follows is a clinician-side explanation of how this medication is used inside a residential level of care, the timing considerations that matter, and how it fits alongside psychiatric treatment for co-occurring conditions. If you are weighing options for yourself or a family member, our admissions team can walk through candidacy in one conversation at 855-778-8668.

How Naltrexone Works in Residential Alcohol Treatment for Adults

Naltrexone is an opioid receptor antagonist. That sounds unrelated to alcohol until you look at what alcohol does in the brain. Drinking triggers the release of endogenous opioids, which in turn drive dopamine release in the reward pathway. That surge is a large part of what makes the first drink reinforcing and the fourth drink hard to refuse. By occupying mu-opioid receptors, naltrexone blunts that reinforcement loop.

Clinically, this shows up in two ways. Some people notice a drop in craving intensity. Others notice that if they do drink, it simply is not as rewarding, which tends to shorten a drinking episode rather than let it escalate. The National Institute on Alcohol Abuse and Alcoholism describes reduction in heavy drinking days as the primary outcome the medication was studied against, which is worth naming plainly: naltrexone is a craving and heavy-drinking medication, not a switch that removes desire entirely.

It is also important to distinguish naltrexone from disulfiram. Disulfiram works by making a person physically ill if they drink. Naltrexone does not. Nobody becomes sick from combining the two. That difference matters for adults who have been told, incorrectly, that any alcohol medication is a punishment mechanism.

When Naltrexone Is Started After Alcohol Withdrawal

Sequencing is where residential care earns its value. A person with a significant alcohol history usually needs medically monitored alcohol detox before any maintenance medication is introduced. Withdrawal is managed with symptom-triggered protocols, structured monitoring, and nursing coverage around the clock, because alcohol withdrawal is one of the few withdrawal syndromes that can become medically dangerous without supervision.

Once acute withdrawal has resolved, typically somewhere in the first three to seven days depending on presentation, the prescriber reviews hepatic function before initiating naltrexone. Baseline liver enzymes are checked because the medication is metabolized hepatically and many adults with long alcohol histories arrive with elevated transaminases. In practice, mildly elevated enzymes are common and are not automatically disqualifying; acute hepatitis or decompensated liver disease is.

The second timing question is opioid exposure. Because naltrexone is an antagonist, giving it to someone who still has opioids on board can precipitate abrupt withdrawal. For anyone with recent opioid use, prescribers generally require an opioid-free interval of roughly seven to ten days and often confirm it before dosing. This is exactly the kind of coordination that is difficult to manage in an outpatient setting and routine inside a residential program, where the treatment team knows precisely what a person has and has not taken.

Level-of-care decisions here follow ASAM criteria, which weigh withdrawal risk, biomedical conditions, psychiatric stability, and recovery environment together rather than looking at substance use in isolation.

Oral Naltrexone Versus the Extended-Release Injection

There are two delivery routes, and the choice usually comes down to adherence realities rather than efficacy debates.

Oral naltrexone is typically dosed at 50 mg daily. It is inexpensive, easy to stop if a side effect appears, and easy to titrate. Its weakness is obvious: it requires a decision every single morning, and early recovery is precisely when daily decisions are hardest.

Extended-release injectable naltrexone is administered as a monthly intramuscular injection. It removes the daily decision entirely for about four weeks. For many adults, the strongest argument for a residential stay is that it creates a window to receive that first injection under medical supervision, observe tolerability, and leave the program already covered rather than leaving with a prescription that may or may not get filled.

Common early side effects with either route include nausea, headache, fatigue, and sleep disruption. Most are transient and manageable. Being inside a program when they appear means a nurse assesses them the same day instead of a person deciding on their own that the medication is not worth it.

Who Is a Candidate, and Who Needs a Different Medication

Naltrexone is not the right answer for everyone, and a good assessment says so out loud. Absolute and relative contraindications include acute hepatitis or hepatic failure, current physiologic opioid dependence, and anticipated need for opioid analgesia, such as an upcoming surgery. Pregnancy requires an individualized risk conversation with an obstetric provider involved.

When naltrexone is not appropriate, acamprosate is often the next consideration, particularly for adults with hepatic concerns since it is renally cleared. Disulfiram remains an option for a narrower group with strong supervision and genuine commitment to abstinence. The point is that medication selection is a clinical decision made by a prescriber who has reviewed labs, history, and co-occurring diagnoses, which is why psychiatric treatment is embedded in the program rather than referred out.

Medication Does Not Replace the Therapy Hours

The most common misunderstanding we encounter is the idea that a medication can carry recovery on its own. It cannot, and no credible guideline suggests otherwise. SAMHSA treatment protocols consistently frame pharmacotherapy as one component of a plan that also includes behavioral treatment, care for co-occurring psychiatric conditions, and support for the people around the individual.

That matters most for adults whose drinking is entangled with something else. A person with post-traumatic stress may be drinking to manage hyperarousal and intrusive memories. A person with a mood disorder may be drinking through untreated depressive episodes. Reducing the reinforcing effect of alcohol without addressing those drivers leaves the underlying condition intact. This is why integrated dual diagnosis care and trauma-informed therapy run in parallel with medication rather than after it. Person-first framing is not softness here; it is accuracy. Alcohol use disorder is a treatable medical condition with identifiable psychiatric and neurobiological drivers, and the treatment plan should address all of them.

Planning the Step-Down Before Discharge

A medication started in a program only helps if it survives the transition out of it. Discharge planning should answer four questions before anyone packs a bag: who is the prescribing clinician going forward, when is the next appointment or injection scheduled, what is the plan if a side effect appears, and what level of care follows residential.

For most adults that means a structured step-down to a partial hospitalization or intensive outpatient program, with the medication continuing uninterrupted through the handoff. Coverage questions get resolved during the stay rather than after it, and our team verifies PPO insurance benefits up front so the financial picture is clear before discharge rather than a surprise afterward.

Duration is individualized. Some people continue naltrexone for several months, others considerably longer. That decision belongs to the person and their prescriber, revisited over time, not fixed at admission.